Skye Bioscience to Participate in Upcoming Investment Conferences

Rhea-AI Summary

Skye Bioscience (NASDAQ: SKYE) will participate in three investor conferences in early December 2025, offering investor access via scheduled 1x1 meetings and two public fireside chats. Key events and dates include:

• Citi Global Healthcare Conference (Miami) — 1x1 meetings on Dec. 2, 2025
• Evercore Annual Healthcare Conference (Coral Gables) — Fireside chat on Dec. 3, 2025 at 12:55 pm ET plus 1x1 meetings
• Piper Sandler Annual Healthcare Conference (New York) — Fireside chat on Dec. 4, 2025 at 11:30 am ET plus 1x1 meetings

Available webcasts will be accessible on Skye's investor website.

News Market Reaction – SKYE

+11.59%

11 alerts

+11.59% News Effect

+7.3% Peak in 4 hr 19 min

+$4M Valuation Impact

$42M Market Cap

0.6x Rel. Volume

On the day this news was published, SKYE gained 11.59%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.3% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $42M at that time.

Data tracked by StockTitan Argus on the day of publication.

San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:

• Citi Global Healthcare Conference (Miami)
  1x1 meetings: Dec. 2

• Evercore Annual Healthcare Conference (Coral Gables)
  Fireside Chat: Dec. 3, 12:55 pm ET
  1x1 meetings

• Piper Sandler Annual Healthcare Conference (New York)
  Fireside Chat: Dec. 4, 11:30 am ET
  1x1 meetings

Available webcasts will be accessible on Skye's website.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

CONTACTS

Investor & Media Relations
ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275680

FAQ

When is Skye Bioscience (SKYE) presenting at the Evercore Annual Healthcare Conference in 2025?

Skye Bioscience will hold a fireside chat on Dec. 3, 2025 at 12:55 pm ET and will conduct 1x1 meetings at the Evercore conference.

What time is the Skye (SKYE) fireside chat at the Piper Sandler Annual Healthcare Conference?

The Piper Sandler fireside chat is scheduled for Dec. 4, 2025 at 11:30 am ET.

How can investors watch Skye Bioscience (SKYE) presentations from the December 2025 conferences?

Available webcasts of Skye's presentations will be accessible on the company's investor relations website.

Which conferences will Skye Bioscience (SKYE) attend in early December 2025?

Skye will attend the Citi Global Healthcare Conference (Miami), Evercore Annual Healthcare Conference (Coral Gables), and Piper Sandler Annual Healthcare Conference (New York).

Does Skye Bioscience (SKYE) have one-on-one investor meetings at the December 2025 conferences?

Yes, Skye has scheduled 1x1 meetings at the Citi, Evercore, and Piper Sandler conferences.